NICE pushes biosimilars in rheumatoid arthritis guidance
September 3, 2015Sales and Marketing
NICE has published final draft guidance confirming its recommended treatment options for rheumatoid arthritis. For the first time copycat, or …
Sandoz launches first US biosimilar
September 3, 2015Manufacturing and Production, Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, biosimilars, filgrastim
Sandoz, the generics arm of the pharma giants Novartis, has become the first company to launch a biosimilar product in …
Shire appoints Sara Mathew to board of directors
September 2, 2015Manufacturing and Production, Research and Development, Sales and Marketing Sara Mathew, Shire
Shire has appointed Sara Mathew to its board of directors as a non-executive director.Mathew will also be a member of …
Pharma ‘spends €40m to sway EU politicians’
September 2, 2015Medical Communications EU, European Commission, TTIP, drug policy, lobbying, transparency
The pharma industry has excessive power over EU decision-makers and spends €40 million a year to influence EU drug policy, …
Amgen and Novartis partner on Alzheimer’s and migraine treatments
September 2, 2015Research and Development Alzheimer's disease, Amgen, Novartis, migraine, neurology, neuroscience
Amgen and Novartis have announced a global collaboration to develop neuroscience treatments in Alzheimer’s disease and migraine. The companies plan …
Two Novartis drugs get first in class EU approvals
September 2, 2015Research and Development, Sales and Marketing Novartis
The European Commission has approved Revolade for severe aplastic anaemia, and the combination of Tafinlar and Mekinist for patients with …
Bayer backs safety of Xarelto after real-world data study
September 2, 2015Research and Development Bayer, ESC, European Society of Cardiology, Xarelto, anticoagulants, atrial fibrillation, real-word evidence, rivaroxaban
Around 96 in every 100 people treated with Bayer’s anticoagulant Xarelto do not experience any major bleeding, related side effects …
Sanofi joins Google in diabetes tech push
September 1, 2015Medical Communications Andy Conrad, Google life sciences, Sanofi, Type 1 diabetes, diabetes, google, type 2 diabetes
Google is continuing its work in diabetes, by teaming up with pharma giants Sanofi to create new digital technologies and …
Standardising the pharma benefit-risk assessment process
September 1, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, FDA, benefit-risk analysis, pharmacoepidemiology, pharmacovigilance
Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view …
Alexion scores double EU approval
September 1, 2015Manufacturing and Production, Sales and Marketing Alexion, EC, European Commission, Kanuma, Strensiq, asfotase alfa, sebelipase alfa, ultra rare disease, ultra-rare disease
Two treatments developed by ultra-rare disease specialists Alexion Pharmaceuticals are now approved for use in Europe. The European Commission approved …
Bristol-Myers Squibb makes big pharma deals
September 1, 2015Manufacturing and Production BMS, Bristol-Myers Squibb, PRM-151, Promedior, QIMR, fibrosis, idiopathic pulmonary fibrosis, immuno-oncology, myelofibrosis
Bristol-Myers Squibb is flexing its muscles in respiratory disease, by signing a deal to acquire the exclusive right to acquire …
FDA issues gliptin joint pain warning
September 1, 2015Manufacturing and Production DPP-4 inhibitors, ESC, FDA, TECOS, adverse effects, drug safety, gliptins, safety alert, safety warning
The FDA has issued a safety alert, warning of joint pain caused by the gliptins, a common class of drugs …
NHS approves electronic consent technology in clinical trials
August 28, 2015Medical Communications, Research and Development Mytrus, NHS, clinical trials, digital health technology, electronic informed consent
Clinical technology and services company Mytrus has announced that its software platform for electronic informed consent has received approval for …
New Boehringer and Lilly type 2 diabetes treatment gets FDA nod
August 28, 2015Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, Synjardy, type 2 diabetes
The FDA has approved Synjardy, from Boehringer Ingelheim and Eli Lilly, for the treatment of adults with type 2 diabetes. …
FDA approves Amgen’s cholesterol lowering drug
August 28, 2015Medical Communications, Research and Development Amgen, FDA, Repatha, evolocumab
The FDA has endorsed Amgen’s cholesterol-lowering medication, Repatha, for the use in patients with high cholesterol. It follows Amgen’s successful …
Moves in pharma app market, but user longevity an issue
August 28, 2015Medical Communications Communication, apps, digital, medcomms, medical communications, mobile
Pharma companies continue to invest in the mobile app market, but studies have found that pharma apps suffer the same …
NHS looks to ESC for next-gen heart drug data
August 28, 2015Medical Communications, Research and Development ALN-PCScs, Repatha, alirocumab, cardiology, cardiovascular disease, cvd, evolocumab, heart disease, high cholesterol, praluent
New data is expected to be presented at the European Cardiology Society congress in London, on the high cholesterol drugs …
Novo Nordisk to buy two pharma research companies
August 27, 2015Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, mergers and acquisitions
Novo Nordisk is to acquire two privately-held biopharmaceutical research companies specialising in diabetes, for undisclosed sums. Calibrium and MB2, formed …
Abbott to table $25bn bid for medical device maker St Jude?
August 27, 2015Manufacturing and Production, Sales and Marketing Abbott Laboratories, mergers and acquisitions, st jude medical
Abbott Laboratories is said to be preparing a $25 billion takeover bid for medical device maker St Jude Medical. Illinois-based Abbott …
Cally Clarkson joins GCI Health as first director of medical education
August 27, 2015Medical Communications Cally Clarkson, GCI Health
GCI Health has appointed Cally Clarkson as its first ever director of medical education. Cally is based in GCI Health’s …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
